Literature DB >> 3010464

Neutralization of HTLV-III/LAV replication by antiserum to thymosin alpha 1.

P S Sarin, D K Sun, A H Thornton, P H Naylor, A L Goldstein.   

Abstract

An antiserum prepared against thymosin alpha 1, a hormone secreted by the thymus gland, effectively neutralized the AIDS-associated virus [HTLV-III/LAV (clone BH-10)] and blocked its replication in H9 cells. Reverse transcriptase activity and expression of the HTLV-III/LAV antigens p15 and p24 were inhibited by purified immunoglobulin G preparations of antisera to thymosin alpha 1. The antiviral activity of the antiserum was found to be due to a region of homology between thymosin alpha 1 and p17, a product of the gag gene of HTLV-III/LAV. Comparison of the primary sequences of thymosin alpha 1 and the gag protein revealed a 44% to 50% homology in an 18-amino acid region, between positions 11 and 28 on thymosin alpha 1 and 92 and 109 on the gag protein. The effectiveness of the thymosin alpha 1 antiserum and of immunoglobulin G-enriched preparations in blocking replication of HTLV-III(BH-10) in H9 cells suggests a novel approach to the development of an AIDS vaccine. A vaccine directed against the gag protein might overcome the problem of genetic drift in the envelope region of the virus and be useful against all genetic variants of HTLV-III/LAV.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3010464     DOI: 10.1126/science.3010464

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  29 in total

Review 1.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

Review 2.  Molecular mimicry as a mechanism for virus-induced autoimmunity.

Authors:  R S Fujinami; M B Oldstone
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

Review 3.  Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

Authors:  E G Sandström; J C Kaplan
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

4.  Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide.

Authors:  K B Cease; H Margalit; J L Cornette; S D Putney; W G Robey; C Ouyang; H Z Streicher; P J Fischinger; R C Gallo; C DeLisi
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

5.  Concomitant infection of HTLV-I and HIV-1: prevalence of IgG and IgM antibodies in Washington, D.C. area.

Authors:  K S Chang; L C Wang; C L Gao; S Alexander; R C Ting; A Bodner; T Log; A F Kuo; P Strickland
Journal:  Eur J Epidemiol       Date:  1988-12       Impact factor: 8.082

6.  Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping.

Authors:  L D Papsidero; M Sheu; F W Ruscetti
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

7.  The human immunodeficiency virus (HIV) gag gene product p18 is responsible for enhanced fusogenicity and host range tropism of the highly cytopathic HIV-1-NDK strain.

Authors:  J de Mareuil; B Brichacek; D Salaun; J C Chermann; I Hirsch
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

8.  Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins.

Authors:  A Ranki; S H Weiss; S L Valle; J Antonen; K J Krohn
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

9.  Prothymosin alpha in human blood.

Authors:  C Panneerselvam; A A Haritos; J Caldarella; B L Horecker
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

Review 10.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.